

- (51) International Patent Classification:
A61K 39/00 (2006.01)

(21) International Application Number:
PCT/EP2024/052002

(22) International Filing Date:
26 January 2024 (26.01.2024)

(25) Filing Language:
English

(26) Publication Language:
English

(30) Priority Data:
23153558.4 26 January 2023 (26.01.2023) EP

(71) Applicant: **AC IMMUNE SA** [CH/CH]; EPFL Innovation Park, Building B, 1015 Lausanne (CH).

(72) Inventors: **STREFFER, Johannes**; c/o AC Immune SA, EPFL Innovation Park, Building B, 1015 Lausanne (CH). **KOSCO-VILBOIS, Marie**; c/o AC Immune SA, EPFL Innovation Park, Building B, 1015 Lausanne (CH). **VUKICEVIC, Marija**; c/o AC Immune SA, EPFL Innovation Park, Building B, 1015 Lausanne (CH).

(74) Agent: **BOULT WADE TENNANT LLP**; Salisbury Square House, 8 Salisbury Square, London EC4Y 8AP (GB).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: ANTI-ABETA VACCINE THERAPY

(57) Abstract: A liposomal vaccine composition comprising a !-amyloid (A β)-derived peptide antigen displayed on the surface of the liposome that comprises, consists essentially of or consists of amino acids 1-15 of A β , a peptide comprising a universal T-cell epitope and an adjuvant comprising monophosphoryl lipid A (MPLA) is used for inducing an anti-A β immune response in a human subject without inducing a serious adverse event. The !-amyloid (A β)-derived peptide antigen (SEQ ID NO: 1) is administered in an amount of 300-2000 μ g. The liposomal vaccine composition is administered intramuscularly or subcutaneously.